GlobeNewswire Inc | Jun 25, 2021 01:16AM EDT

June 25, 2021



Libtayo (cemiplimab) approved bythe European Commissionas the first immunotherapy indicated for patients with advanced basal cell carcinoma

-- Approval based on data from the largest trial to date in patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor -- Libtayo now approved by the European Commission for three advanced cancers

PARIS and TARRYTOWN, NY June25, 2021 The European Commission (EC) has approved Sanofi and Regenerons PD-1 inhibitor Libtayo (cemiplimab) to treat adults with locally advanced or metastatic basal cell carcinoma (BCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).

BCC is the most common type of skin cancer worldwide, representing up to 80% of non-melanoma skin cancers, and incidence is increasing across many European countries. While the large majority of BCCs are caught early and easily cured with surgery and/or radiation, a small proportion of cases can develop into advanced BCC and penetrate deeper into surrounding tissues (locally advanced) or spread to other parts of the body (metastatic), becoming more difficult to treat.

Since its launch in Europe just two years ago, Libtayo has redefined the standard of care for advanced CSCC and has the potential to do the same in advanced BCC, said Peter C. Adamson, M.D., Global Development Head, Oncology at Sanofi. Together with Regeneron, were committed to addressing gaps in the treatment of advanced forms of non-melanoma skin cancer.

Libtayo is now approved for three advanced cancers in the European Union, following the ECs concurrent approval of Libtayo for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumor cells have 50% PD-L1 expression and no EGFR, ALK or ROS1 aberrations. In 2019, Libtayo was approved by the EC as the first treatment for adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation. Across all of its approved indications, Libtayo had a generally consistent safety profile. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue during or after treatment with Libtayo.

The EC approval in BCC is based on data from the largest prospective clinical trial (n=119) in patients with advanced BCC previously treated with an HHI to date. Libtayo-treated patients with locally advanced BCC experienced an objective response rate (ORR) of 32% (95% confidence interval [CI]: 22-43) (25% partial response, 7% complete response) by independent central review. Libtayo-treated patients with metastatic BCC demonstrated an ORR of 29% (95% CI: 15-46) (26% partial response, 3% complete response) by investigator assessment. In addition, approximately 90% of patients across both groups had a duration of response (DOR) of 6 months or longer per Kaplan Meier estimates, and the median DOR has not been reached for either group. Median duration of follow-up was 16 months for locally advanced BCC and 9 months for metastatic BCC.

Safety was assessed in 816 patients across all four Libtayo monotherapy pivotal trials in its approved indications. Adverse events were serious in 30% ofpatients and led to permanent discontinuation in 8%of patients. Immune-related adverse reactions occurred in 22%of patients and led to permanent discontinuation in 4% of patients. The most common immune-related adverse reactions were hypothyroidism (8%), hyperthyroidism (3%), pneumonitis (3%), hepatitis (2%), colitis (2%) and immune-related skin adverse reactions (2%).

Libtayoisthe first immunotherapy to show a clinical benefit in patients with advanced BCC after HHI therapy in a pivotal trial, and with this first-in-class approval has the potential to transform treatment for patients in Europe whose cancer has progressed despite HHI treatment, said Israel Lowy, M.D., Ph.D., Senior Vice President, Translational and Clinical Sciences, Oncology at Regeneron. We look forward to continuing to investigate this medicine in additional settings, with the goal of helping more patients with difficult-to-treat cancers around the world.

About the Phase 2 Trial in Advanced BCC

The EC approval was based on data from an ongoing open-label, multi-center, non-randomized Phase 2 trial of patients with unresectable locally advanced BCC or metastatic BCC (nodal or distant). Patients in both cohorts had either progressed on HHI therapy, had not had an objective response after 9 months on HHI therapy, or were intolerant of prior HHI therapy. The primary efficacy endpoint was confirmed ORR, and a key secondary endpoint was DOR, assessed by independent central review.

About Libtayo

Libtayo is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation.

The recommended dose of Libtayo is 350 mg administered as an intravenous infusion over 30 minutes every three weeks, until disease progression or unacceptable toxicity. Libtayo is available as a single-dose 350 mg vial. No PD-L1 or tumor mutational burden (TMB) testing is required before starting treatment with Libtayo for advanced BCC.

The extensive clinical program for Libtayo is focused on difficult-to-treat cancers. Current clinical development programs include Libtayo in combination with chemotherapy for advanced NSCLC irrespective of PD-L1 expression and Libtayo monotherapy for advanced cervical cancer. Libtayo is also being investigated in combination with either conventional or novel therapeutic approaches for other solid tumors and blood cancers.These potential uses are investigational, and their safety and efficacy have not been evaluated by any regulatory authority.

The generic name for Libtayo in its approvedU.S.indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the U.S. Food and Drug Administration (FDA). Libtayo is being jointly developed by Regeneron and Sanofi under a global collaboration agreement.

About Regeneron

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite technologies, such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.



About Sanofi

Sanofi is dedicated to supporting people through their health challenges. Weare a global biopharmaceutical company focused on human health. We preventillness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millionswith long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transformingscientific innovation into healthcare solutions around the globe.

Investor Relations - ParisMedia Relations Contacts Eva Schaefer-JansenAshleigh Koss Arnaud DelepineTel: +1 (908) 205-2572 Natalie Phamashleigh.koss@sanofi.com

Investor Relations ? North America Felix Lauscher Fara Berkowitz Suzanne Greco



IR main line: Tel.: +33 (0)1 53 77 45 45 investor.relations@sanofi.com https://www.sanofi.com/en/ investors/contactRegeneronMedia Relations Contact RegeneronInvestorRelationsTaylor Ramsey ContactsTel: +1 914-847-5459 Vesna Tosictaylor.ramsey@regeneron.com Tel: +1 914-847-5443 vesna.tosic@regeneron.com





Sanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in thePrivate Securities Litigation Reform Act of 1995, as amended. Forward-lookingstatements are statements that are not historical facts. These statementsinclude projections and estimates regarding the marketing and other potentialof the product, or regarding potential future revenues from the product.Forward-looking statements are generally identified by the words ?expects?,?anticipates?, ?believes?, ?intends?, ?estimates?, ?plans? and similarexpressions. Although Sanofi?s management believes that the expectationsreflected in such forward-looking statements are reasonable, investors arecautioned that forward-looking information and statements are subject tovarious risks and uncertainties, many of which are difficult to predict andgenerally beyond the control of Sanofi, that could cause actual results anddevelopments to differ materially from those expressed in, or implied orprojected by, the forward-looking information and statements. These risks anduncertainties include among other things, unexpected regulatory actions ordelays, or government regulation generally, that could affect the availabilityor commercial potential of the product, the fact that product may not becommercially successful, the uncertainties inherent in research anddevelopment, including future clinical data and analysis of existing clinicaldata relating to the product, including post marketing, unexpected safety,quality or manufacturing issues, competition in general, risks associated withintellectual property and any related future litigation and the ultimateoutcome of such litigation, and volatile economic and market conditions, andthe impact that COVID-19 will have on us, our customers, suppliers, vendors,and other business partners, and the financial condition of any one of them, aswell as on our employees and on the global economy as a whole. Any materialeffect of COVID-19 on any of the foregoing could also adversely impact us. Thissituation is changing rapidly and additional impacts may arise of which we arenot currently aware and may exacerbate other previously identified risks. Therisks and uncertainties also include the uncertainties discussed or identifiedin the public filings with the SEC and the AMF made by Sanofi, including thoselisted under ?Risk Factors? and ?Cautionary Statement Regarding Forward-LookingStatements? in Sanofi?s annual report on Form 20-F for the year ended December31, 2020. Other than as required by applicable law, Sanofi does not undertakeany obligation to update or revise any forward-looking information orstatements.

Regeneron Forward-Looking Statements and Use of Digital MediaThis press release includes forward-looking statements that involve risks anduncertainties relating to future events and the future performance of RegeneronPharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events orresults may differ materially from these forward-looking statements. Words suchas "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate,"variations of such words, and similar expressions are intended to identify suchforward-looking statements, although not all forward-looking statements containthese identifying words. These statements concern, and these risks anduncertainties include, among others, the impact of SARS-CoV-2 (the virus thathas caused the COVID-19 pandemic) on Regeneron's business and its employees,collaborators, and suppliers and other third parties on which Regeneron relies,Regeneron's and its collaborators' ability to continue to conduct research andclinical programs, Regeneron's ability to manage its supply chain, net productsales of products marketed or otherwise commercialized by Regeneron and/or itscollaborators (collectively, "Regeneron's Products"), and the global economy;the nature, timing, and possible success and therapeutic applications ofRegeneron's Products and product candidates being developed by Regeneron and/orits collaborators (collectively, ?Regeneron?s Product Candidates?) and researchand clinical programs now underway or planned, including without limitation Libtayo^ (cemiplimab) for the treatment of locally advanced or metastaticbasal cell carcinoma; uncertainty of the utilization, market acceptance, andcommercial success of Regeneron's Products (such as Libtayo) and Regeneron?sProduct Candidates and the impact of studies (whether conducted by Regeneron orothers and whether mandated or voluntary), including the study discussed inthis press release, on any of the foregoing; the likelihood, timing, and scopeof possible regulatory approval and commercial launch of Regeneron's ProductCandidates and new indications for Regeneron's Products, such as possibleregulatory approval of Libtayo in combination with chemotherapy for advancednon-small cell lung cancer irrespective of PD-L1 expression and as monotherapyfor advanced cervical cancer (as well as in combination with eitherconventional or novel therapeutic approaches for both solid tumors and bloodcancers); the ability of Regeneron's collaborators, suppliers, or other thirdparties (as applicable) to perform manufacturing, filling, finishing,packaging, labeling, distribution, and other steps related to Regeneron'sProducts and Regeneron?s Product Candidates; the ability of Regeneron tomanufacture and manage supply chains for multiple products and productcandidates; safety issues resulting from the administration of Regeneron'sProducts (such as Libtayo) and Regeneron?s Product Candidates in patients,including serious complications or side effects in connection with the use ofRegeneron's Products and Regeneron?s Product Candidates in clinical trials;determinations by regulatory and administrative governmental authorities whichmay delay or restrict Regeneron's ability to continue to develop orcommercialize Regeneron's Products and Regeneron?s Product Candidates,including without limitation Libtayo; ongoing regulatory obligations andoversight impacting Regeneron's Products, research and clinical programs, andbusiness, including those relating to patient privacy; the availability andextent of reimbursement of Regeneron's Products from third-party payers,including private payer healthcare and insurance programs, health maintenanceorganizations, pharmacy benefit management companies, and government programssuch as Medicare and Medicaid; coverage and reimbursement determinations bysuch payers and new policies and procedures adopted by such payers; competingdrugs and product candidates that may be superior to, or more cost effectivethan, Regeneron's Products and Regeneron?s Product Candidates; the extent towhich the results from the research and development programs conducted byRegeneron and/or its collaborators may be replicated in other studies and/orlead to advancement of product candidates to clinical trials, therapeuticapplications, or regulatory approval; unanticipated expenses; the costs ofdeveloping, producing, and selling products; the ability of Regeneron to meetany of its financial projections or guidance and changes to the assumptionsunderlying those projections or guidance; the potential for any license,collaboration, or supply agreement, including Regeneron's agreements withSanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respectiveaffiliated companies, as applicable), to be cancelled or terminated; and risksassociated with intellectual property of other parties and pending or futurelitigation relating thereto (including without limitation the patent litigationand other related proceedings relating to EYLEA^ (aflibercept) Injection,Dupixent^ (dupilumab), Praluent^ (alirocumab), and REGEN-COV? (casirivimaband imdevimab)), other litigation and other proceedings and governmentinvestigations relating to the Company and/or its operations, the ultimateoutcome of any such proceedings and investigations, and the impact any of theforegoing may have on Regeneron's business, prospects, operating results, andfinancial condition. A more complete description of these and other materialrisks can be found in Regeneron's filings with the U.S. Securities and ExchangeCommission, including its Form 10-K for the year ended December 31, 2020 andits Form 10-Q for the quarterly period ended March 31, 2021. Anyforward-looking statements are made based on management's current beliefs andjudgment, and the reader is cautioned not to rely on any forward-lookingstatements made by Regeneron. Regeneron does not undertake any obligation toupdate (publicly or otherwise) any forward-looking statement, including withoutlimitation any financial projection or guidance, whether as a result of newinformation, future events, or otherwise.

Regeneron uses its media and investor relations website and social mediaoutlets to publish important information about the Company, includinginformation that may be deemed material to investors. Financial and otherinformation about Regeneron is routinely posted and is accessible onRegeneron's media and investor relations website ( http://newsroom.regeneron.com) and its Twitter feed ( http://twitter.com/regeneron).





Attachment

-- 2021_06_25_SANOFI_LIBTAYO_BCC_EC_Approval_PR_EN